Core Viewpoint - Xianle Health's stock price has shown a year-to-date increase of 26.74%, indicating positive market performance despite a recent decline of 2.07% on September 12 [2][1]. Company Overview - Xianle Health Technology Co., Ltd. was established on August 16, 1993, and went public on September 25, 2019. The company is based in Shantou, Guangdong Province and specializes in the research, production, sales, and technical services of nutritional health products [2]. - The company's revenue composition includes soft capsules (46.38%), gummies (25.31%), tablets (9.26%), beverages (5.42%), hard capsules (5.31%), powders (4.45%), and other forms (3.22%) [2]. Financial Performance - For the first half of 2025, Xianle Health reported a revenue of 2.042 billion yuan, representing a year-on-year growth of 2.57%. The net profit attributable to shareholders was 161 million yuan, reflecting a growth of 4.30% compared to the previous year [2]. - Since its A-share listing, Xianle Health has distributed a total of 583 million yuan in dividends, with 415 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Xianle Health reached 12,100, an increase of 9.08% from the previous period. The average number of circulating shares per shareholder was 21,172, up by 19.00% [2]. - Notable institutional shareholders include招商产业精选股票A (holding 2.2 million shares) and东方红核心价值混合A (holding 1.8095 million shares), both of which are new entrants among the top ten circulating shareholders [3].

以下为业绩说明会问答实录： 根据全景数据后台统计，在今天的交流过程中，来自全国多个省、市地区的投资者共向上市公司提问7 个，公司嘉宾共回答问题7个，答复率100.00%，充分实现了上市公司与投资者的良好互动。 1、问：董事减持进度如何，没有发布呢。还没开始减持吗？ 2025年09月05日，仙乐健康2025年半年度网上业绩说明会在全景网顺利举行。出席本次业绩说明会的人 员有董事长、总经理林培青、副总经理、代理财务负责人郑丽群、副总经理、董事会秘书刘若阳、独立 董事高见、保荐代表人刘兴德。 回答：尊敬的投资者，您好！董事减持计划相关进展公司将及时按照法律法规履行信息披露义务。感谢 您的关注！ 回答：尊敬的投资者，您好！由于公司2016年12月收购Sirio Germany和2023年1月收购美国Best Formulations均属于非同一控制下的企业合并，根据《企业会计准则》，购买方对合并成本大于合并中 取得的被购买方可辨认净资产公允价值份额的差额，应当确认为商誉。2024年末进行了商誉减值测试结 果为暂无减值风险。公司将Sirio Germany和美国Best Formulations纳入公司业务发展总体规划 ...

Group 1 - The core point of the article is that Xianle Health announced that its Vice General Manager, Zheng Liqiong, increased her shareholding through a block trade on September 8, 2025, acquiring 140,000 shares, which represents 0.05% of the total share capital, with an investment amount of 3.15 million yuan [1] Group 2 - The shareholding increase indicates a positive signal regarding the company's confidence in its future performance [1] - The transaction was conducted through a block trade, which is often seen as a strategic move to minimize market impact [1] - The amount invested by Zheng Liqiong reflects a significant personal commitment to the company's growth [1]

（文章来源：证券日报） 证券日报网讯 9月9日晚间，仙乐健康发布公告称，公司于2025年9月9日收到公司副总经理、代理财务 负责人郑丽群女士出具的《关于增持公司股份的告知函》，基于对公司未来持续稳定发展的信心以及对 公司股票长期投资价值的认可，郑丽群女士于2025年9月8日以其自有资金通过深圳证券交易所交易系统 以大宗交易方式增持公司股份140，000股，占公司总股本剔除公司回购证券专用账户中的股份后股本总 数306，033，360股的0.05%。 ...

格隆汇9月9日丨仙乐健康(300791.SZ)公布，公司于2025年9月9日收到公司副总经理、代理财务负责人 郑丽群女士出具的《关于增持公司股份的告知函》，基于对公司未来持续稳定发展的信心以及对公司股 票长期投资价值的认可，郑丽群女士于2025年9月8日以其自有资金通过深圳证券交易所交易系统以大宗 交易方式增持公司股份14万股，占公司总股本剔除公司回购证券专用账户中的股份后股本总数 306,033,360股的0.05%。 ...

截至发稿，仙乐健康市值为77亿元。 每经头条（nbdtoutiao）——雷军挥泪"斩"王腾，小米爱将泄密"失街亭"，大厂正风肃纪"拼牙口" （记者 王晓波） 每经AI快讯，仙乐健康（SZ 300791，收盘价：25元）9月9日晚间发布公告称，仙乐健康科技股份有限 公司于2025年9月9日收到公司副总经理、代理财务负责人郑丽群女士出具的《关于增持公司股份的告知 函》，基于对公司未来持续稳定发展的信心以及对公司股票长期投资价值的认可，郑丽群女士于2025年 9月8日以其自有资金通过深圳证券交易所交易系统以大宗交易方式增持公司股份14万股，占公司总股本 剔除公司回购证券专用账户中的股份后股本总数约3.06亿股的0.05%。 2025年1至6月份，仙乐健康的营业收入构成为：软胶囊占比46.38%，软糖占比25.31%，片剂占比 9.26%，功能饮品占比5.42%，硬胶囊占比5.31%。 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-087 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于高级管理人员增持公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日收到公 司副总经理、代理财务负责人郑丽群女士出具的《关于增持公司股份的告知函》， 基于对公司未来持续稳定发展的信心以及对公司股票长期投资价值的认可，郑丽 群女士于 2025 年 9 月 8 日以其自有资金通过深圳证券交易所交易系统以大宗交 易方式增持公司股份 140,000 股，占公司总股本剔除公司回购证券专用账户中的 股份后股本总数 306,033,360 股的 0.05%。现将相关情况公告如下： 一、增持主体基本情况 1、增持主体：公司副总经理、代理财务负责人郑丽群女士。 2、本次增持前持股情况：郑丽群女士在本次增持前持有公司股份 354,632 股，占公司总股本剔除公司回购证券专用账户中 ...

2025 年 9 月 5 日投资者关系活动记录表 仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 编号： 2025-004 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（ ） 参与单位名称 及人员姓名 投资者网上提问 时间 2025 年 9 月 5 日 15:30-17:30 方式 公司通过"全景·路演天下"（https://rs.p5w.net/）采用网络远程的方式 召开业绩说明会 上市公司 接待人员姓名 公司董事长兼总经理：林培青 副总经理、代理财务负责人：郑丽群 副总经理、董事会秘书：刘若阳 独立董事：高见 保荐代表人：刘兴德 投资者关系活 动主要内容介 问题：美洲市场收入同比增长 4.26，其中出口业务克服关税影响同增 7.4，请问公司是如何应对关税问题，未来在美洲市场有什么具体的拓展 1 仙乐健康科技股份有限公司 投资者关系活动记录表 绍 计划 答：公司积极采取多种手段控制对等关税对美出口业务的影响：首先，公 ...

Investment Rating - The report rates the health supplement industry as "Outperform" [1] Core Insights - The health supplement industry is entering a new upward cycle, driven by rising health awareness among younger consumers and the emergence of new consumption trends [6][9] - The market for nutritional health products in China is projected to reach 522.3 billion yuan by 2024, with a compound annual growth rate of 5.7% from 2019 to 2024 [10][11] - Online sales channels are becoming increasingly important, with a significant rise in sales through platforms like Douyin, which has become the leading online sales platform for health supplements [32][35] Summary by Sections Industry Characteristics - The industry is characterized by a clear trend towards younger consumers, the emergence of new niche markets, and accelerated product iteration [7][9] - The overall scale of the traditional health supplement market is over 300 billion yuan, growing at approximately 5% annually, while new consumption segments such as anti-aging and cardiovascular health are emerging [9] Market Dynamics - The online sales of health supplements in China grew from 107.4 billion yuan in 2022 to 142.1 billion yuan in 2023, indicating a strong shift towards e-commerce [29][30] - Douyin's sales growth in health supplements reached 38% in the first half of 2025, surpassing other platforms like Tmall and JD [32] Key Segments - The report identifies several high-growth segments within the health supplement industry: - Anti-aging: Focused on products like ergothioneine and NAD+ [49][52] - Sports nutrition: Emphasizing glucosamine and calcium products [55] - Cardiovascular health: Highlighting deep-sea fish oil and phospholipid products [58] - Liver health: Addressing needs arising from unhealthy lifestyles [61] - Probiotics: Targeting gut health and overall wellness [66] Investment Recommendations - The report suggests focusing on brands with strong product operation capabilities and high brand recognition, such as Ruoyuchen and H&H International Holdings [5][69] - For production, it recommends selecting leading companies with substantial scale and customer resources, such as Xianle Health [5][69] - In the raw material sector, it highlights industry leaders like Jindawei [5][69]

Core Viewpoint - The food and beverage industry is experiencing a mixed performance, with some companies showing growth while others face challenges due to market adjustments and inventory pressures [2][8][9]. Market Performance - The Shanghai and Shenzhen 300 Index fell by 0.81%, while the Shenwan Food and Beverage Index decreased by 1.5% during the specified period [1]. - The top five gaining stocks included Huanlejia, Gaisi Food, Qianwei Yangchu, Baihe Co., and Huifa Food [1]. Institutional Insights - Open-source Securities suggests focusing on three lines: national mid-to-high-end recovery, regional leaders, and high-end liquor valuation recovery [2]. - Key companies to watch include Shede Liquor, Shanxi Fenjiu, Gujing Gongjiu, and Moutai, with a focus on new consumption trends and channels [2]. - Huachuang Securities recommends exploring new opportunities in the health product sector, particularly H&H International and Xianle Health [3]. Industry Trends - The liquor industry is undergoing a rational adjustment, with companies like Moutai and Zhenjiu Liudu exploring new paths to enhance market reach [7]. - The white liquor sector is seeing a significant inventory issue, with 20 listed liquor companies holding nearly 170 billion yuan in inventory, leading to cash flow pressures for some mid-tier companies [9]. Company Developments - Wuliangye has launched a promotional campaign allowing car buyers to purchase its liquor at a 25% discount [10][11]. - Yingjia Gongjiu has established a new sales company to enhance its market presence [12]. - Jiusuan Co. has adjusted its growth strategy, focusing on maintaining market share rather than absolute growth [13]. Macro Events - The Chinese warehousing index for August was reported at 49.3%, indicating a decline in new orders and a slowdown in goods turnover, which may impact the food and beverage sector [4]. - The emergence of H5N1 avian influenza in the UK could have implications for poultry-related food products [5]. Financial Metrics - The financial performance of the liquor industry shows a significant disparity, with 15 out of 21 listed companies reporting revenue declines, while only six managed to achieve growth [8]. - The industry is expected to face continued challenges, with some analysts predicting a prolonged adjustment period before recovery [8]. Inventory and Capacity Issues - Many liquor companies are struggling with high inventory levels, with some facing a six-year inventory turnover cycle, which could further strain cash flow [9]. - Despite low capacity utilization rates, some companies continue to expand production, raising concerns about future inventory management [9].